Recent News

• 11.09.2026 - Mereo BioPharma Reports Third Quarter 2026 Financial Results
• 08.11.2026 - Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
• 08.11.2026 - Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
• 05.12.2026 - Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
• 03.19.2026 - Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
• 01.12.2026 - Mereo BioPharma Provides Corporate Update
• 12.29.2025 - Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
• 11.10.2025 - Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
• 08.12.2025 - Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
• 08.12.2025 - Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Recent Filings

• 11.09.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.09.2026 - 8-K Current report
• 11.09.2026 - EX-99.1 EX-99.1
• 10.28.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.19.2026 - 8-K Current report
• 08.14.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.11.2026 - EX-99.1 EX-99.1
• 08.11.2026 - 8-K Current report
• 08.11.2026 - 8-K Current report
• 08.11.2026 - EX-99.1 EX-99.1